These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

671 related items for PubMed ID: 25132654

  • 1. Effect of thrombopoietin receptor agonists on the apoptotic profile of platelets in patients with chronic immune thrombocytopenia.
    Mitchell WB, Pinheiro MP, Boulad N, Kaplan D, Edison MN, Psaila B, Karpoff M, White MJ, Josefsson EC, Kile BT, Bussel JB.
    Am J Hematol; 2014 Dec; 89(12):E228-34. PubMed ID: 25132654
    [Abstract] [Full Text] [Related]

  • 2. Thrombopoietin receptor agonists in patients with persistent or chronic immune thrombocytopenia.
    Agnelli Giacchello J, Valeri F, Boccadoro M, Borchiellini A.
    Eur J Haematol; 2018 Mar; 100(3):304-307. PubMed ID: 29243329
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Thrombopoietin: too much or too little.
    Newland A.
    Hematology; 2012 Apr; 17 Suppl 1():S166-8. PubMed ID: 22507811
    [Abstract] [Full Text] [Related]

  • 7. Thrombopoietin Receptor Agonists in Children with Immune Thrombocytopenia: A New Therapeutic Era.
    Lassandro G, Palladino V, Vecchio GCD, Palmieri VV, Corallo PC, Faienza MF, Giordano P.
    Endocr Metab Immune Disord Drug Targets; 2021 Apr; 21(3):397-406. PubMed ID: 32473624
    [Abstract] [Full Text] [Related]

  • 8. Is there any Role for Splenectomy in Adulthood Onset Chronic Immun e Thrombocytopenia in the Era of TPO Receptors Agonists? A Critic al Overview.
    Vibor M, Rogulj IM, Ostojic SK.
    Cardiovasc Hematol Disord Drug Targets; 2017 Jul 04; 17(1):38-51. PubMed ID: 28034281
    [Abstract] [Full Text] [Related]

  • 9. Thrombopoietin receptor agonist switch in adult primary immune thrombocytopenia patients: A retrospective collaborative survey involving 4 Spanish centres.
    Lakhwani S, Perera M, Fernández-Fuertes F, Ríos de Paz MA, Torres M, Raya JM, Hernández MT.
    Eur J Haematol; 2017 Oct 04; 99(4):372-377. PubMed ID: 28759125
    [Abstract] [Full Text] [Related]

  • 10. Thrombocytopenia in MDS: epidemiology, mechanisms, clinical consequences and novel therapeutic strategies.
    Li W, Morrone K, Kambhampati S, Will B, Steidl U, Verma A.
    Leukemia; 2016 Mar 04; 30(3):536-44. PubMed ID: 26500138
    [Abstract] [Full Text] [Related]

  • 11. Treatment patterns and clinical outcomes in patients with chronic immune thrombocytopenia (ITP) switched to eltrombopag or romiplostim.
    Kuter DJ, Macahilig C, Grotzinger KM, Poston SA, Wang PF, Dawson KL, Ward M.
    Int J Hematol; 2015 Mar 04; 101(3):255-63. PubMed ID: 25586660
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Thrombopoietin receptor agonists for preparing adult patients with immune thrombocytopenia to splenectomy: results of a retrospective, observational GIMEMA study.
    Zaja F, Barcellini W, Cantoni S, Carpenedo M, Caparrotti G, Carrai V, Di Renzo N, Santoro C, Di Nicola M, Veneri D, Simonetti F, Liberati AM, Ferla V, Paoloni F, Crea E, Volpetti S, Tuniz E, Fanin R.
    Am J Hematol; 2016 May 04; 91(5):E293-5. PubMed ID: 26910388
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Thrombopoietin level predicts response to treatment with eltrombopag and romiplostim in immune thrombocytopenia.
    Al-Samkari H, Kuter DJ.
    Am J Hematol; 2018 Dec 04; 93(12):1501-1508. PubMed ID: 30187942
    [Abstract] [Full Text] [Related]

  • 16. [Successful switching from eltrombopag to romiplostim in a pediatric patient with refractory chronic ITP].
    Mori M, Kato M, Koh K, Hanada R.
    Rinsho Ketsueki; 2015 May 04; 56(5):511-3. PubMed ID: 26062675
    [Abstract] [Full Text] [Related]

  • 17. Sequential treatment with thrombopoietin-receptor agonists (TPO-RAs) in immune thrombocytopenia (ITP): experience in our center.
    González KJ, Zuluaga SO, DaRos CV, Rodríguez PP, Martí AC.
    Ann Hematol; 2017 Mar 04; 96(3):507-508. PubMed ID: 27975127
    [No Abstract] [Full Text] [Related]

  • 18. [Thrombosis during thrombopoietin receptor agonist treatment for immune thrombocytopenia. A French multicentric observational study].
    Weber E, Moulis G, Mahévas M, Guy C, Lioger B, Durieu I, Hunault M, Ramanantsoa M, Royer B, Default A, Pérault-Pochat MC, Moachon L, Bernard N, Bardy G, Jonville-Bera AP, Geniaux H, Godeau B, Cathébras P.
    Rev Med Interne; 2017 Mar 04; 38(3):167-175. PubMed ID: 27793553
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. New therapeutic options for immune thrombocytopenia.
    Schipperus M, Fijnheer R.
    Neth J Med; 2011 Mar 04; 69(11):480-5. PubMed ID: 22173361
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 34.